aldosterone and Neoplasm Metastasis studies

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research Excerpts

Excerpt	Relevance	Reference
"This Phase II study was designed to determine the efficacy and tolerability of vorozole (R83842), a new nonsteroidal aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression being treated with tamoxifen, and to correlate these effects with the hormonal profile and plasma drug levels."	9.08	Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. ( Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA, 1995)
" While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone."	6.36	Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977)
"This Phase II study was designed to determine the efficacy and tolerability of vorozole (R83842), a new nonsteroidal aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression being treated with tamoxifen, and to correlate these effects with the hormonal profile and plasma drug levels."	5.08	Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. ( Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA, 1995)
"Both medroxyprogesterone acetate (MPA) and megestrol acetate (MA) are effective in the treatment of metastatic breast cancer."	5.05	[Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies]. ( Blossey, HC; Emrich, D; Nagel, GA; Wander, HE, 1985)
"Endocrine hypertension is a term used for states in which hormone derangements result in clinically significant hypertension."	2.43	Incidentally discovered masses in hypertensive patients. ( Cicala, MV; Mantero, F; Sartorato, P, 2006)
" While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone."	2.36	Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977)
"Aldosterone was found by the double radioisotopic technique in the neoplastic tissue."	1.25	Primary aldosteronism due to a malignant ovarian tumor. ( Borsatti, A; Mantero, F; Terribile, V; Todesco, S, 1975)

Research

Studies (25)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

A1C Level

Timeframe	Studies, this research(%)	All Research%
pre-1990	19 (76.00)	18.7374
1990's	2 (8.00)	18.2507
2000's	2 (8.00)	29.6817
2010's	2 (8.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Feldman, RD	1
Ding, Q	1
Hussain, Y	1
Limbird, LE	1
Pickering, JG	1
Gros, R	1
Berthon, A	1
Sahut-Barnola, I	1
Lambert-Langlais, S	1
de Joussineau, C	1
Damon-Soubeyrand, C	1
Louiset, E	1
Taketo, MM	1
Tissier, F	1
Bertherat, J	1
Lefrançois-Martinez, AM	1
Martinez, A	1
Val, P	1
DALMAU-CIRIA, M	1
RIVADENEYRA, J	1
BRORSON, I	1
Mansmann, G	1
Lau, J	1
Balk, E	1
Rothberg, M	1
Miyachi, Y	1
Bornstein, SR	1
Cicala, MV	1
Sartorato, P	1
Mantero, F	2
Bencsik, Z	1
Szabolcs, I	1
Kovács, Z	1
Ferencz, A	1
Vörös, A	1
Kaszás, I	1
Bor, K	1
Gönczi, J	1
Góth, M	1
Kovács, L	1
Dohán, O	1
Szilágyi, G	1
Goss, PE	1
Clark, RM	1
Ambus, U	1
Weizel, HA	1
Wadden, NA	1
Crump, M	1
Walde, D	1
Tye, LM	1
De Coster, R	1
Bruynseels, J	1
Todesco, S	1
Terribile, V	1
Borsatti, A	1
Santen, RJ	2
Samojlik, E	1
Lipton, A	2
Harvey, H	2
Ruby, EB	1
Wells, SA	2
Kendall, J	1
Haagensen, DE	1
Ruby, EJ	1
Dilley, WG	1
Bosl, GJ	2
Leitner, SP	2
Atlas, SA	2
Sealey, JE	2
Preibisz, JJ	2
Scheiner, E	2
Shitikov, BD	1
Mavrichev, AS	1
Sukonko, OG	1
Kosheleva, MI	1
Maslova, GT	1
Wander, HE	1
Blossey, HC	1
Nagel, GA	1
Emrich, D	1
Mellinger, RC	1
Petermann, FL	1
Jurgenson, JC	1
Vieweg, WV	1
Reitz, RE	1
Weinstein, RL	1
Green, MF	1
Baxter, RH	1
Wang, I	1
Givens, JR	1
Camacho, A	1
Patterson, P	1
Goldman, AG	1
Micale, J	1
Zavod, R	1
Blann, LR	1
Patrick, CE	1
Schambelan, M	1
Slaton, PE	1
Murray, JF	1
Biglieri, EG	1
Abelson, D	1
Bulaschenko, H	1
Trommer, PR	1
Valdes-Dapena, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism[NCT01990560]	Phase 4	8 participants (Actual)	Interventional	2013-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in hyperglycemia assessed by HbA1c, also known as glycated hemoglobin (NCT01990560)
Timeframe: Baseline, 3 months, and 6 months

Body Mass Index (BMI)

Intervention	percentage of red blood cells (Mean)
	Baseline	3 months	6 months
Mifepristone	6.2	6.1375	6.125

Change in metabolic syndrome as assessed by BMI (NCT01990560)
Timeframe: Baseline and 6 months

CushingQoL

Intervention	kg/m2 (Mean)
	Baseline	6 months
Mifepristone	35.1538	34.5463

Change in Quality of Life - as assessed by the Cushing's Quality of Life questionnaire (CushingQoL). Patient completed questionnaire, 12 items, each scored on a 5 point score, resulting in a score of 12 (worst) to 60 (best) where higher scores indicate more favorable QOL. (NCT01990560)
Timeframe: Baseline and 6 months

Fasting Lipid Profile

Intervention	units on a scale (Mean)
	Baseline	6 months
Mifepristone	37.2857	38.7857

Change in metabolic syndrome as assessed by fasting lipid profile which includes Low-density lipoproteins ( LDL), High-density lipoproteins (HDL), and Triglycerides (Trigs) levels, and total cholesterol which is the sum of HDL plus LDL and 20% of trigs. (NCT01990560)
Timeframe: Baseline and 6 months

HOMA-IR

Intervention	mg/dL (Mean)
	Total Cholesterol Baseline	Total Cholesterol 6 months	LDL baseline	LDL 6 months	HDL Baseline	HDL 6 months	Trigs Baseline	Trigs 6 months
Mifepristone	178.63	171.43	97.88	104.37	59.13	46.86	107.88	100.29

Change in hyperglycemia assessed by Homeostatic Model Assessment of Insulin Resistance, HOMA-IR (a validated assessment of insulin resistance). HOMA-IR = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. (NCT01990560)
Timeframe: Baseline and 6 months

Hospital Anxiety and Depression Scale (HADS)

Intervention	HOMA-IR score (Mean)
	Baseline	6 months
Mifepristone	2.418	1.465

Change in Quality of Life as assessed by the Hospital Anxiety and Depression Scale (HADS). Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression (NCT01990560)
Timeframe: Baseline and 6 months

Nottingham Health Profile (NHP)

Intervention	units on a scale (Mean)
	Baseline	6 months
Mifepristone	16.2857	11.1667

Change in Quality of Life as assessed by the Nottingham Health Profile (NHP) which is a patient reported questionnaire to measure a patient's view of their own health status. There are 6 sections (Energy level, Pain, Emotional Reaction, Sleep, Social Isolation, and Physical Abilities. All questions have only yes/no answer options and each section score is weighted so that the possible score range for any section is 0-100. The higher the score, the greater the number and severity of problems. (NCT01990560)
Timeframe: Baseline and 6 months

Quality of Life

Intervention	units on a scale (Mean)
	Energy Level (EL) Baseline	EL 6 months	Pain (P) Baseline	P 6 months	Emotional Reaction (ER) Baseline	ER 6 months	Sleep (S) Baseline	S 6 months	Social Isolation (SI) Baseline	SI 6 months	Physical Abilities (PA) Baseline	PA 6 months
Mifepristone	32.60	45.40	24.88	32.08	27.03	35.09	24.87	31.15	20.09	31.15	23.06	27.49

Change in Quality of Life as assessed by the Beck Depression Inventory. a 21-question multiple choice, self-report inventory that is used for measuring the severity of anxiety. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms. (NCT01990560)
Timeframe: Baseline and 6 months

State Trait Anxiety Inventory (STAI)

Intervention	units on a scale (Mean)
	Baseline	6 months
Mifepristone	16.1429	11.7143

Change in Quality of Life - as assessed by the State Trait Anxiety Inventory (STAI). The State-Trait Anxiety Inventory both state and trait anxiety separately. Each type of anxiety has its own scale of 20 different questions that are scored and averaged. Total scores range from 20 to 80, with higher scores correlating with greater anxiety. (NCT01990560)
Timeframe: Baseline and 6 months

Waist Circumference

Intervention	units on a scale (Mean)
	Baseline	6 months
Mifepristone	25.4286	28.8571

Change in metabolic syndrome as assessed by waist circumference (NCT01990560)
Timeframe: Baseline and 6 months

Weight

Intervention	cm (Mean)
	Baseline	6 months
Mifepristone	103.25	99.3125

Change in metabolic syndrome as assessed by weight (NCT01990560)
Timeframe: Baseline and 6 months

Article	Year
The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine reviews, 2004, Volume: 25, Issue:2 Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenal Glands; Adrenalectomy; Aldosterone; Bioma	2004
Incidentally discovered masses in hypertensive patients. Best practice & research. Clinical endocrinology & metabolism, 2006, Volume: 20, Issue:3 Topics: Adenoma; Adrenal Gland Neoplasms; Aldosterone; Cushing Syndrome; Diagnostic Imaging; Humans; Hyperte	2006
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer, 1977, Volume: 39, Issue:6 Suppl Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy	1977

Article	Year
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3 Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast	1995
[Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies]. Klinische Wochenschrift, 1985, Apr-01, Volume: 63, Issue:7 Topics: Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Breast Neoplasms; Female; Humans; Hydrocortis	1985
Effect of aminoglutethimide and reserpine on the human pituitary-adrenal axis: remission of a case of Cushing's disease. Metabolism: clinical and experimental, 1970, Volume: 19, Issue:10 Topics: 17-Hydroxycorticosteroids; Addison Disease; Adrenal Glands; Adult; Aldosterone; Aminoglutethimide; A	1970

Article	Year
Aldosterone mediates metastatic spread of renal cancer via the G protein-coupled estrogen receptor (GPER). FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016, Volume: 30, Issue:6 Topics: Aldosterone; Animals; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Kid	2016
Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Human molecular genetics, 2010, Apr-15, Volume: 19, Issue:8 Topics: Adrenal Cortex; Adrenal Gland Neoplasms; Aldosterone; Animals; beta Catenin; Cell Proliferation; Dis	2010
[HYPERNATRIURIA AND HYPONATREMIA WITH NORMAL HYDRATION: SCHWARTZ-BARTTER SYNDROME]. Medicina clinica, 1963, Volume: 41 Topics: Aldosterone; Brain Neoplasms; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lung Neoplasms; Natr	1963
[INVESTIGATION OF THE BIOLOGICAL ACTIVITIES OF TRIAMCINOLONE DIACETATE IN PATIENTS WITH ADRENAL INSUFFICIENCY]. Revista medica del Hospital General, 1964, Volume: 27 Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adrenalectomy; Aldosterone; Blood; Blood Pressure; B	1964
SYNDROME OF MINERALOCORTICOID EXCESS ILLUSTRATED BY A CASE HISTORY OF TWO TUMOURS OF THE ADRENAL CORTEX IN ONE PATIENTS. Acta chirurgica Scandinavica, 1964, Volume: 128 Topics: Adenoma; Adrenal Cortex; Adrenal Gland Neoplasms; Adrenocortical Hyperfunction; Aldosterone; Blood C	1964
Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:5 Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and ov	1996
Primary aldosteronism due to a malignant ovarian tumor. The Journal of clinical endocrinology and metabolism, 1975, Volume: 41, Issue:5 Topics: Adrenal Glands; Adult; Aldosterone; Child; Female; Humans; Hyperaldosteronism; Neoplasm Metastasis;	1975
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Annals of surgery, 1978, Volume: 187, Issue:5 Topics: Adrenal Cortex; Adrenalectomy; Aldosterone; Aminoglutethimide; Androstenedione; Bone Neoplasms; Brea	1978
Altered renin and aldosterone excretion in patients treated for metastatic germ cell tumours. International journal of andrology, 1987, Volume: 10, Issue:1 Topics: Aldosterone; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cisplatin; Cyc	1987
[The aldosterone level as a probable prognostic factor in patients with kidney cancer]. Voprosy onkologii, 1989, Volume: 35, Issue:1 Topics: Adult; Aged; Aldosterone; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis;	1989
Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:11 Topics: Adult; Aldosterone; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Electrolytes; Humans;	1986
Hyponatremia with low urinary aldosterone occurring in an old woman. The Journal of clinical endocrinology and metabolism, 1972, Volume: 34, Issue:1 Topics: 17-Hydroxycorticosteroids; Addison Disease; Adrenal Glands; Adrenocorticotropic Hormone; Aged; Aldos	1972
Addison's disease secondary to metastatic carcinoma: an example of adrenocortical and adrenomedullary insuffiency. Cancer, 1973, Volume: 31, Issue:5 Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Addison Disease; Adenocarcinoma; Adrenal Glands; Adrenoc	1973
Roy Douglas Wright. The Australian journal of experimental biology and medical science, 1972, Volume: 50, Issue:7 Topics: Aldosterone; Australia; Biological Evolution; Biophysics; Cerebral Cortex; Gastric Mucosa; History,	1972
Endocrine disorders in the elderly. British medical journal, 1974, Feb-09, Volume: 1, Issue:5901 Topics: Acidosis; Aged; Aldosterone; Blood Glucose; Calcitonin; Diabetes Mellitus; Diet Therapy; Endocrine S	1974
Malignant hypertension in a patient with Conn's syndrome. Scottish medical journal, 1974, Volume: 19, Issue:4 Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aldosterone; Arteriosclerosis; Autopsy; Bronchial Neoplasms	1974
Salt wasting syndrome of obscure origin. The American journal of medicine, 1969, Volume: 46, Issue:4 Topics: Aldosterone; Cystadenoma; Female; Humans; Hyponatremia; Kidney Tubules; Middle Aged; Neoplasm Metast	1969
Adrenal insufficiency and inappropriate secretion of antidiuretic hormone. Occurrence in a patient with carcinoma of the lung. Archives of internal medicine, 1969, Volume: 124, Issue:2 Topics: 17-Hydroxycorticosteroids; Adenocarcinoma; Adrenal Gland Neoplasms; Adrenal Glands; Adrenal Insuffic	1969
Malignant interstitial-cell tumor of the testis treated with o,p'-DDD. Metabolism: clinical and experimental, 1966, Volume: 15, Issue:3 Topics: 17-Ketosteroids; Aldosterone; Antineoplastic Agents; Dichlorodiphenyldichloroethane; Estrogens; Gona	1966

aldosterone and Neoplasm Metastasis